https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-06850&r=1
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive,...
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
a studyin combination
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2016-01211
Alisertib with or without Fulvestrant in Treating Patients with Locally Advanced or Metastatic,...
Alisertib with or without Fulvestrant in Treating Patients with Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
locally advancedalisertibwithoutfulvestrant
https://www.biospace.com/puma-biotechnology-announces-phase-ii-clinical-trial-design-for-alisertib-in-her2-negative-hormone-receptor-positive-metastatic-breast-cancer
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone...
Dec 11, 2023 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company (the Company), announced the design of the Phase II trial of alisertib for the treatment...
phase ii clinical trial
https://www.biospace.com/puma-biotechnology-announces-presentation-of-findings-from-a-phase-i-ii-study-of-alisertib-and-pembrolizumab-for-rb-deficient-head-and-neck-squamous-cell-carcinomas-at-the-2023-aacr-nci-eortc-molecular-targets-and-cancer-therapeutics-meeting
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and...
Oct 16, 2023 - Puma Biotechnology, Inc. announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with...